Patient Assistance Programs and the Anti-Kickback Statute: Charting a Pathway Forward

Document Type

Article

Publication Date

3-10-2022

ISSN

1538-3598

Publisher

JAMA Network

Language

en-US

Abstract

In the US health care system, as millions of patients remain uninsured and many more experience substantial cost exposures through deductibles, coinsurance, and co-payments, some have turned to patient assistance programs for help in paying for expensive prescription drugs. Patient assistance programs provide subsidies that allow patients to meet their out-of-pocket payment obligations when filling prescriptions for expensive drugs. Although patient assistance programs are generally nonprofit entities, they often receive substantial support from pharmaceutical manufacturers. These programs work by either acquiring and providing drugs at little or no cost to patients or by providing subsidies (including coupons) that offset patient out-of-pocket costs for drugs that are reimbursed by insurers. The latter approach raises broader policy and legal questions, especially where public insurers, like Medicare, are involved.

This document is currently not available here.

Link to Publisher Site

Share

COinS